1. Milton AL, Everitt BJ. The persistence of maladaptive memory: Addiction, drug memories and anti-relapse treatments. Neurosci Biobehav Rev. 2012; 36(4): 1119-39. [DOI] [PubMed]

2. Rich MT, Torregrossa MM. Maladaptive memory mechanisms in addiction and relapse. 2019: 103-22. [DOI]

3. Sinha R, Shaham Y, Heilig M. Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology (Berl). 2011; 218(1): 69-82. [DOI] [PubMed]

4. Kassani A, Niazi M, Hassanzadeh J, Menati R. Survival analysis of drug abuse relapse in addiction treatment centers. Int J High Risk Behav Addict. 2015; 4(3): e23402. (Persian) [DOI] [PubMed]

5. Hon T, Das RK, Kamboj SK. The effects of cognitive reappraisal following retrieval-procedures designed to destabilize alcohol memories in high-risk drinkers. Psychopharmacology (Berl). 2016; 233(5): 851-61. [DOI] [PubMed]

6. Torregrossa MM, Taylor JR. Learning to forget: Manipulating extinction and reconsolidation processes to treat addiction. Psychopharmacology (Berl). 2013; 226(4): 659-72. [DOI] [PubMed]

7. Monfils MH, Holmes EA. Memory boundaries: Opening a window inspired by reconsolidation to treat anxiety, trauma-related, and addiction disorders. Lancet Psychiatry. 2018; 5(12): 1032-42. [DOI] [PubMed]

8. Walsh KH, Das RK, Saladin ME, Kamboj SK. Modulation of naturalistic maladaptive memories using behavioural and pharmacological reconsolidation-interfering strategies: A systematic review and meta-analysis of clinical and 'sub-clinical' studies. Psychopharmacology (Berl). 2018; 235(9): 2507-27. [DOI] [PubMed]

9. Liu JF, Tian J, Li JX. Modulating reconsolidation and extinction to regulate drug reward memory. Eur J Neurosci. 2019; 50(3): 2503-12. [DOI] [PubMed]

10. Taibi S. Propranolol's effects on memory reconsolidation in patients with PTSD. 2019.

11. Kindt M, Soeter M, Sevenster D. Disrupting reconsolidation of fear memory in humans by a noradrenergic beta-blocker. J Vis Exp. 2014(94). [DOI] [PubMed]

12. Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats-a possible mechanism for the persistence of traumatic memories in PTSD. Depress Anxiety. 2011; 28(3): 186-93. [DOI] [PubMed]

13. Villain H, Benkahoul A, Drougard A, Lafragette M, Muzotte E, Pech S, et al. Effects of propranolol, a beta-noradrenergic antagonist, on Memory consolidation and reconsolidation in Mice. Front Behav Neurosci. 2016; 10:49. [DOI] [PubMed]

14. Thomas E, Saumier D, Pitman RK, Tremblay J, Brunet A. Consolidation and reconsolidation are impaired by oral propranolol administered before but not after memory (re) activation in humans. Neurobiol Learn Mem. 2017; 142(Pt A): 118-25. [DOI] [PubMed]

15. Wolter M, Huff AE, Baidoo N, Jardine KH, Pulles Z, Winters BD, et al. Modulation of object memory consolidation by heroin and heroin-conditioned stimuli: Role of opioid and noradrenergic systems. Eur Neuropsychopharmacol. 2020; 33: 146-57. [DOI] [PubMed]

16. Sorg BA. Reconsolidation of drug memories. Neurosci Biobehav Rev. 2012; 36(5): 1400-17. [DOI] [PubMed]

17. Chesworth R, Corbit LH. Noradrenergic beta-receptor antagonism in the basolateral amygdala impairs reconsolidation, but not extinction, of alcohol self-administration: Intra-BLA propranolol impairs reconsolidation of alcohol self-administration. Neurobiol Learn Mem. 2018;151:59-70. [DOI] [PubMed]

18. Xue YX, Deng JH, Chen YY, Zhang LB, Wu P, Huang GD, et al. Effect of selective inhibition of reactivated nicotine-associated memories with propranolol on nicotine craving. JAMA Psychiatry. 2017; 74(3): 224-32. [DOI] [PubMed]

19. Lonergan M, Saumier D, Tremblay J, Kieffer B, Brown TG, Brunet A. Reactivating addiction-related memories under propranolol to reduce craving: A pilot randomized controlled trial. J Behav Ther Exp Psychiatry. 2016; 50: 245-9. [DOI] [PubMed]

20. Zhao LY, Sun LL, Shi J, Li P, Zhang Y, Lu L. Effects of beta-adrenergic receptor blockade on drug-related memory reconsolidation in abstinent heroin addicts. Drug Alcohol Depend. 2011; 118(2-3): 224-9. [DOI] [PubMed]

21. Otis JM, Werner CT, Mueller D. Noradrenergic regulation of fear and drug-associated memory reconsolidation. Neuropsychopharmacology. 2015; 40(4): 793-803. [DOI]

22. Chalkia A, Weermeijer J, Van Oudenhove L, Beckers T. Acute but not permanent effects of propranolol on fear memory expression in humans. Front Hum Neurosci. 2019; 13:51. [DOI]

23. Cogan ES, Shapses MA, Robinson TE, Tronson NC. Disrupting reconsolidation: Memory erasure or blunting of emotional/motivational value? Neuropsychopharmacology. 2019. 44(2): 399–407. [DOI] [PubMed]

24. Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A. Propranolol's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: A meta-analysis. J Psychiatry Neurosci. 2013; 38(4): 222-31. [DOI] [PubMed]

25. Exton-McGuinness MTJ, Milton AL. Reconsolidation blockade for the treatment of addiction: Challenges, new targets, and opportunities. Learn Mem. 2018; 25(9): 492-500. [DOI] [PubMed]

26. Saladin ME, Gray KM, McRae-Clark AL, Larowe SD, Yeatts SD, Baker NL, et al. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl). 2013; 226(4): 721-37. [DOI] [PubMed]

27. Motamed N, Zamani F. Sample size in medicin research: Applied Method. 1th ed. Tehran: Asre Roshan Bini Publication; 2017.

28. First MB. Structured clinical interview for the DSM(SCID). 2015: 1-6. [DOI]

29. Shankman SA, Funkhouser CJ, Klein DN, Davila J, Lerner D, Hee D. Reliability and validity of severity dimensions of psychopathology assessed using the structured clinical interview for DSM-5 (SCID). Int J Methods Psychiatr Res. 2018; 27(1):e1590. [DOI] [PubMed]

30. Mohammadkhani P, Forouzan AS, Hooshyari Z, Abasi I. Psychometric properties of persian version of structured clinical interview for DSM-5-research version (SCID-5-RV): A diagnostic Accuracy study. Iranian Journal of Psychiatry and Behavioral Sciences. 2020; 14(2): e100930. (Persian) [DOI]

31. Heather N, Luce A, Peck D, Dunbar B, James I. Development of a treatment version of the readiness to change questionnaire. Addiction Research. 2009; 7(1): 63-83. [DOI]

32. Defuentes-Merillas L, Dejong CA, Schippers GM. Reliability and validity of the dutch version of the readiness to change questionnaire. Alcohol Alcohol. 2002; 37(1): 93-9. [DOI] [PubMed]

33. Heather N, Hönekopp J. A revised edition of the readiness to change questionnaire [Treatment Version]. Addiction Research & Theory. 2008; 16(5): 421–433. [DOI]

34. Rollnick S, Heather N, Gold R, Hall W. Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict. 1992; 87(5): 743-54. [DOI] [PubMed]

35. Crackau B, Loehrmann I, Zahradnik A, Otto C, John U, Bischof G, et al. Measuring readiness to change for problematic consumption of prescription drugs: Development of an adapted and shortened Readiness to change questionnaire. Addiction Research & Theory. 2010; 18(1): 110-8. [DOI]

36. Vasconcelos AG, Malloy-Diniz L, Correa H. Systematic review of psychometric proprieties of barratt impulsiveness scale version 11 (BIS-11). Clinical Neuropsychiatry. 2012; 9(2): 61-74.

37. Javid M, Mohammadi N, Rahimi C. Psychometric properties of an Iranian version of the barratt impulsiveness scale-11 (BIS-11). Psychological Methods and Models. 2012; 2(8): 23-34. (Persian)

38. Ekhtiari H, Safaei H, Esmaeeli Djavid G, Atefvahid MK, Edalati H, Mokri A. Reliability and validity of Persian versions of eysenck, barratt, dickman and zuckerman questionnaires in assessing risky and impulsive behaviors. IJPCP. 2008; 14(3): 326-36. (Persian)

39. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol. 1988; 54(6): 1063-70. [DOI] [PubMed]

40. Ekhtiari H, Edalati H, Behzadi A, Safaei H, Noori M, Mokri A. Designing and evaluation of reliability and validity of five visual cue-induced craving tasks for different groups of opiate abusers. IJPCP. 2008; 14(3): 337-49. (Persian)

41. Diaz-Garcia A, Gonzalez-Robles A, Mor S, Mira A, Quero S, Garcia-Palacios A, et al. Positive and negative affect schedule (PANAS): Psychometric properties of the online spanish version in a clinical sample with emotional disorders. BMC Psychiatry. 2020; 20(1): 56. [DOI] [PubMed]

42. Gyollai A, Simor P, Koteles F, Demetrovics Z. Psychometric properties of the hungarian version of the original and the short form of the positive and negative affect schedule (PANAS). neuropsychopharmacol hung. 2011; 13(2): 73-9. [PubMed]

43. Merz EL, Malcarne VL, Roesch SC, Ko CM, Emerson M, Roma VG, et al. Psychometric properties of Positive and negative affect schedule (PANAS) original and short forms in an african american community sample. J Affect Disord. 2013; 151(3): 942-9. [DOI] [PubMed]

44. Serafini K, Malin-Mayor B, Nich C, Hunkele K, Carroll KM. Psychometric properties of the Positive and Negative Affect Schedule (PANAS) in a heterogeneous sample of substance users. Am J Drug Alcohol Abuse. 2016; 42(2): 203-12. [DOI] [PubMed]

45. Schramm MJ, Everitt BJ, Milton AL. Bidirectional modulation of alcohol-associated memory reconsolidation through manipulation of adrenergic signaling. Neuropsychopharmacology. 2016; 41(4): 1103-11. [DOI] [PubMed]

46. Soeter M, Kindt M. High trait anxiety: A challenge for disrupting fear memory reconsolidation. PLoS One. 2013; 8(11): e75239. [DOI] [PubMed]

47. Janak PH, Bowers MS, Corbit LH. Compound stimulus presentation and the norepinephrine reuptake inhibitor atomoxetine enhance long-term extinction of cocaine-seeking behavior. Neuropsychopharmacology. 2012; 37(4): 975-85. [DOI] [PubMed]

48. Leung HT, Corbit LH. Extinction of alcohol seeking is enhanced by compound extinction and the noradrenaline reuptake inhibitor atomoxetine. Addict Biol. 2017; 22(1): 47-57. [DOI] [PubMed]

49. Pachas GN, Gilman J, Orr SP, Hoeppner B, Carlini SV, Grasser EB, et al. Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues. Psychopharmacology (Berl). 2015; 232 (9): 1619-28. [DOI] [PubMed]

50. Enkema MC, Hallgren KA, Neilson EC, Bowen S, Bird ER, Larimer ME. Disrupting the path to craving: Acting without awareness mediates the link between negative affect and craving. Psychol Addict Behav. 2020; 34(5): 620-7. [DOI] [PubMed]